Swiss Biotech Numab Therapeutics raises CHF 22 million

09.03.2020 15:38, Gianmaria Sbetta

Numab Therapeutics announced today the closing of its Series B financing round at a total volume of CHF 22M. Alongside with existing investors this financing round was joined by 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd.

Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area focusing on cancer immunotherapy by creating multispecific antibodies that enable the pursuit of novel therapeutic strategies. The MATCH™ technology platform is fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. 

The biotech startup closed a CHF 15 million Series B financing round in December 2019 and with the new financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development of a number of programs towards the clinic. The company also plans to initiate a clinical trial for its lead oncology program ND021 during the course of 2020.

Numab Therapeutics made it to TOP 100 Swiss startups Award in 2013 and 2014.